[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335323-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335323-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","identication-of-gi3-as-a-promising-molecular-oncotarget-of-pancreatic-cancer","Identiﬁcation of Gαi3 as a promising molecular oncotarget of pancreatic cancer","","Rising pancreatic cancer mortality globally drives the search for novel therapeutic targets. This study examines G protein inhibitory subunit 3 (Gαi3) expression, function, and mechanism in pancreatic cancer, using bioinformatics, cell experiments, pathway assays, and in vivo xenografts. Results show Gαi3 overexpression correlates with poor prognosis and aggressive disease, and that Gαi3 knockdown/knockout suppresses viability, proliferation, cell cycle progression, and mobility. Mechanistically, Gαi3 modulates Akt-mTOR and PKA–Hippo-YAP signaling and influences immune microenvironments, including macrophage and PD-L1 patterns.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/identication-of-gi3-as-a-promising-molecular-oncotarget-of-pancreatic-cancer/335323/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/identication-of-gi3-as-a-promising-molecular-oncotarget-of-pancreatic-cancer/335323.png","ImageObject",300,407,{"name":42,"@type":43},"Riley","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the key role of Gαi3 in pancreatic cancer according to this study?","Question",{"text":63,"@type":64},"Gαi3 is overexpressed in pancreatic cancer and promotes tumor cell growth. Reducing or eliminating Gαi3 significantly decreases viability, proliferation, and mobility while overexpression enhances growth.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does Gαi3 influence signaling pathways in pancreatic cancer cells?",{"text":68,"@type":64},"Gαi3 depletion reduces Akt-mTOR activity and increases PKA activity, activating Hippo signaling through LATS1/2 and inactivating YAP/TAZ. Gαi3 overexpression produces opposite effects on these pathways.",{"name":70,"@type":61,"acceptedAnswer":71},"What regulatory factor is linked to Gαi3 expression, and what happens when it is altered?",{"text":72,"@type":64},"The study identifies increased binding between the Gαi3 promoter and the transcription factor TCF7L2. Gαi3 expression decreases after TCF7L2 silencing and increases after TCF7L2 overexpression.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335323,1790421028,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nIdentiﬁcation of Gαi3 as a promising molecular oncotarget of pancreatic cancer  \nJian-zhuo Jiang 1,6, Yin-biao Qiao2,6, Xiao-ren Zhu3,6, Qian-hui Gu3,6, Jing-jing Lu 3, Zhen-yu Ye 4 ✉, Lu Xu 5 ✉ and  1 ✉  \nYuan-yuan Liu   \n© The Author(s) 2024  \n\n|  | The increasing mortality rate of pancreatic cancer globally necessitates the urgent identiﬁcation for novel therapeutic targets. This study investigated the expression, functions, and mechanistic insight of G protein inhibitory subunit 3 (Gαi3) in pancreatic cancer. Bioinformatics analyses reveal that Gαi3 is overexpressed in human pancreatic cancer, correlating with poor prognosis, higher tumor grade, and advanced classiﬁcation. Elevated Gαi3 levels are also conﬁrmed in human pancreatic cancer tissues and primary/ immortalized cancer cells. Gαi3 shRNA or knockout (KO) signiﬁcantly reduced cell viability, proliferation, cell cycle progression, and mobility in primary/immortalized pancreatic cancer cells. Conversely, Gαi3 overexpression enhanced pancreatic cancer cell growth. RNA-sequencing and bioinformatics analyses of Gαi3-depleted cells indicated Gαi3’s role in modulating the Akt-mTOR and PKAHippo-YAP pathways. Akt-S6 phosphorylation was decreased in Gαi3-depleted cells, but was increased with Gαi3 overexpression. Additionally, Gαi3 depletion elevated PKA activity and activated the Hippo pathway kinase LATS1/2, leading to YAP/TAZinactivation, while Gαi3 overexpression exerted the opposite effects. There is an increased binding between Gαi3 promoter and the transcription factor TCF7L2 in pancreatic cancer tissues and cells. Gαi3 expression was signiﬁcantly decreased following TCF7L2 silencing, but increased with TCF7L2 overexpression. In vivo, intratumoral injection of Gαi3 shRNA-expressing adenoassociated virus signiﬁcantly inhibited subcutaneous pancreatic cancer xenografts growth in nude mice. A signiﬁcant growth reduction was also observed in xenografts from Gαi3 knockout pancreatic cancer cells. Akt-mTOR inactivation and increased PKA activity coupled with YAP/TAZ inactivation were also detected in xenograft tumors upon Gαi3 depletion. Furthermore, bioinformatic analysis and multiplex immunohistochemistry (mIHC) staining on pancreatic cancer tissue microarrays showed a reduced proportion of M1-type macrophages and an increase in PD-L1 positive cells in Gαi3-high pancreatic cancer tissues. Collectively, these ﬁndings highlight Gαi3’s critical role in promoting pancreatic cancer cell growth, potentially through the |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| modulation of the Akt-mTOR and PKA-Hippo-YAP pathways and its inﬂuence on the immune landscape. |  |  |\n|  | Cell Death and Disease (2024)15:699; [https://doi.org/10.1038/s41419-024-07079-6](https://doi.org/10.1038/s41419-024-07079-6) |  |\n|  |  |  |\n\nINTRODUCTION  \nPancreatic cancer persists as a predominant cause of cancerrelated mortality worldwide, with its incidence doubling over the past two decades [1] . Characterized by advanced presentation, including systemic metastasis and inoperability at diagnosis, pancreatic cancer is associated with a notably poor prognosis, evidenced by overall ﬁve-year survival less than 10%[2–4] . The efﬁcacy of conventional treatment modalities, such as radiotherapy and gemcitabine-based chemotherapy, remains constrained for patients with unresectable pancreatic cancers [5, 6] . Despite advancements in genomic diagnostics and introduction of molecularly targeted therapies improving outcomes for advanced pancreatic cancer patients, the overall survival remains grim [7] .  \nThe pathogenesis of pancreatic cancer is signiﬁcantly inﬂuenced by the aberrant expression and persistent activation of  \nvarious cell surface receptor tyrosine kinases (RTKs), ","cbCaikV96erD91lt","https://ap.wps.com/l/cbCaikV96erD91lt","pdf",11291594,"English","# Introduction\n## Disease burden and therapeutic limitations\n## RTK signaling, resistance, and need for new targets\n# Results\n## Gαi3 overexpression and clinical correlation\n## Functional inhibition by Gαi3 knockdown/knockout and enhancement by overexpression\n## Pathway regulation (Akt-mTOR, PKA, Hippo-YAP)\n## TCF7L2 regulation of Gαi3\n## In vivo xenograft effects of Gαi3 depletion\n## Immune landscape changes in human tumor tissues","[{\"question\":\"What is the key role of Gαi3 in pancreatic cancer according to this study?\",\"answer\":\"Gαi3 is overexpressed in pancreatic cancer and promotes tumor cell growth. Reducing or eliminating Gαi3 significantly decreases viability, proliferation, and mobility while overexpression enhances growth.\"},{\"question\":\"How does Gαi3 influence signaling pathways in pancreatic cancer cells?\",\"answer\":\"Gαi3 depletion reduces Akt-mTOR activity and increases PKA activity, activating Hippo signaling through LATS1/2 and inactivating YAP/TAZ. Gαi3 overexpression produces opposite effects on these pathways.\"},{\"question\":\"What regulatory factor is linked to Gαi3 expression, and what happens when it is altered?\",\"answer\":\"The study identifies increased binding between the Gαi3 promoter and the transcription factor TCF7L2. Gαi3 expression decreases after TCF7L2 silencing and increases after TCF7L2 overexpression.\"}]","Identiﬁcation of Gαi3 as a promising molecular oncotarget of pancreatic cancer | PDF",1790010529,48]